Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4395 - Phase II study of Ccr-based dose-control of S-1 in the first-line chemotherapy of S-1 /oxaliplatin(SOX)+bevacizumab regimen for advanced colorectal cancer


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Colon and Rectal Cancer




Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


D. MANAKA, R. Nishitai, S. Konishi, T. Ohta, T. Hattori, H. Ann, K. Kawaguchi, Y. Nishikawa, R. Kudo, S. Hamasu

Author affiliations

  • Dept. Of Surgery, Gastrointestinal Center, Kyoto Katsura Hospital, 615-8256 - Kyoto/JP


Abstract 4395


In the 1st line therapy of metastatic colorectal cancer(mCRC), SOX+Bevacizumb(Bev) regimen (L-OHP: 130 mg/m2 day 1, Bev: 7.5 mg/kg day 1, S-1: 80, 100, 120 mg*/body days 1–14 repeated every 3 weeks, *According to body surface area, BSA < 1.25 m2, BSA ≥ 1.25 to 

Trial design

This trial is an open-label, multi-center, phase 2 study. Before administration of SOX regimen, Ccr is measured. The patients with Ccr >_70, the standard dose will be administered, and in the patients with Ccr 70>_60, the level 1 dose control (decrease) will be performed, and in the patients with Ccr 60>_50, the level 2 dose control will be performed (in the patients

Clinical trial identification


Legal entity responsible for the study

Kyoto Katsura Hospital




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.